In a retrospective review of psoriasis patients seen at the Mayo Clinic the frequency of pathologically confirmed myopathies or inflammation in muscle in patients with psoriasis was estimated to be 0.13%. However, this could be an overestimate, given potential referral bias. Concomitant autoimmune disorders, psoriatic arthritis, and exposure to anti-TNF-a therapy were the proposed associations with increased risk of developing myopathy in psoriasis patients. Most had inclusion of body myositis. Key learning points: Evidence suggests that the appropriate treatment with immunosuppressants allows a normal pregnancy without major problemsand with no further risk for post-partum relapse. This is presuming the disease is well-controlled for 6monthsprior to conception. There is no definite impact of pregnancy on a well-controlled myositis, although case reports havevariable outcomes. Pregnancy outcomes are better if the disease is fully controlled preconception and there is no cardiac or respiratory involvement. Hence, preconception work up is done in liaison with maternal foetal medicine and includes disease activity measurements, repeat investigations for systemic involvement (commonly ECHO and pulmonary function test), repeat autoimmune screen and individualised preconception counselling. Poorlycontrolleddiseasecanincreaseriskof intrauterinegrowth retardation, stillbirth or preterm birth. Uncontrolled inflammation is thought to result in poor placental circulation due toinflammatory fibrillin deposition. Autoimmune disorders are conventionally known to flare postpartum but experiences are variable. We observed a slight CK rise postpartum which settled without needing further treatment. Treatment options available for women considering pregnancy include glucocorticoids and intravenous immunoglobulin for induction of remission and remission with azathioprine,cyclosporin ortacrolimus. Data available is from case series and experiences of specialist centres only, hence there is scope for further research. Owing to limited data on the long-term use of intravenous immunoglobulins in myositis, absence of evidence-based treatment options for calcification in myositis and push for switch to rituximab due to cost implications, further management of patients in similar situations will be challenging.
Introduction: The link between ovarian malignancy and paraneoplastic dermatomyositis is well established. Association with underlying benign ovarian pathology is much less certain, with only scarce case report evidence available. This represents the first case of dermatomyositis with associated bilateral ovarian chocolate cysts. Case description: A 45-year-old female presented with classical features of dermatomyositis, with a background of hypertension and non-alcoholic fatty liver disease. She had proximal limb weakness, neck flexor weakness, dysphagia and dysphonia, accompanied by a scaly, erythematous rash over her face, chest, abdomen and lateral thighs. Serum creatine kinase (CK) at presentation was 4923 IU/L. An MRI scan of her thighs showed widespread muscle oedema affecting both legs and the pelvis, including the quadriceps, iliacus and psoas muscles. A punch biopsy of the skin on her thigh showed only post inflammatory pigmentation. Lung volumes were reduced (FEV1 69% predicted). Video fluoroscopy confirmed moderate-severe pharyngeal stage dysphagia. CT scan of the chest, abdomen and pelvis revealed enlarged, unilocular cysts in each ovary, the right cyst measuring 7 cm and the left, 5 cm in maximal diameter. Subsequent transvaginal ultrasound confirmed bilateral unilocular, thick walled cysts with a ground-glass appearance, which would be consistent with benign endometriomas. A further interval ultrasound after 1 month showed no change in their appearance or size. Serum CA125was 104 kU/L. The patient was treated with 3 pulses of 1g intravenous (IV) methylprednisolone, followed by 2 courses of IV immunoglobulin 2g/kg over 5 days. This was followed by a gradually reducing course of oral prednisolone, starting at 50mg OD PO alongside 15mg weekly of oral methotrexate. She has responded well to treatment, with near normalisation of her objective manual muscle testing scores and normalisation of the serum CK value. Surgery is now planned for a total abdominal hysterectomy and bilateral oophorectomy. Discussion: Extensive investigation has not demonstrated any other underlying malignancy to account for the development of dermatomyositis. Initial limited and unsustained clinical response to IV methylprednisolone prompted further treatment with IV immunoglobulin. Surgical histology results are now awaited to confirm the suspected diagnosis. It will be very interesting to see if surgical removal of the cysts has any impact on the clinical manifestationof disease. Key learning points: Benign ovarian pathology should not be dismissed as a potential underlying mechanism for development of dermatomyositis. Conflicts of interest: The authors have declared no conflicts of interest.
A CASE OF SAE-1 DERMATOMYOSITIS
Ashraful Haque 1 , Tejal Patel 2 , and Rakesh Kumari 2 1 Rheumatology, Doncaster Royal Infirmary, Doncaster, United Kingdom, and 2 Rheumatology, Rotherham General Hospital, Rotherham, United Kingdom Introduction: Dermatomyositis is a rare, acquired inflammatory myopathy. The panel of myositis specific antibodies (MSAs) continues to grow and inclusivity of MSAs in myositis autoantibody testing can vary among trusts.Ourpatient had serology and clinical features inkeeping inflammatory myopathy associated with one of the more recently found MSAs-SAE-1. Case description: A 63-year-old man developed a purple rash over his scalp in July 2018. He was previously fit and well apart from childhood rheumatic fever. He was a non-smoker. The rash spread over his face, forearms and feet. He developed discomfort and weakness in his neck, upper arms and thighs in September 2018 with increasing difficulty walking up stairs and lifting boxes and driving. In October 2018 he developed progressive dysphagia and was struggling to swallow semi-solid food and then liquids too. A skin biopsy showed mild papillary dermal inflammatory infiltrate in keeping with possible dermatomyositis or systemic lupus. The patient was admitted to hospital in December 2018 with progression of the rash, proximal weakness and swallowing difficulty and referred to rheumatology. He lost over 7kgs in weight between October and December 2018. He denied any fever or symptoms suggestive of a connective tissue disease. On examination he had a purple rash on his scalp, over the malar distribution and upper back. He had a heliotrope rash over his eyelids and gottrens papules. He had 4/5 weakness in hip and shoulder flexors. He also had bibasal crepitations from hislungs on auscultation. Investigations revealed aserial normal creatine kinase (CK) and transaminases. A myositis panel revealed the SAE-1 autoantibody. CT thorax, abdomen and pelvis revealed some inflammatory changes at the bases of both lungs in keeping with organising pneumonia. Upper and lower GI endoscopy was unremarkable. An MRI revealed inflammation of multiple muscles including gluteus maximus and minimus, iliopsoas, paraspinal muscles and posterior abdominal wall in keeping with polymyositis. He was commenced on prednsiolone 40mg for 3 months after a pulse intravenous methylprednisolone. He noticed great improvement with proximal myopathy, dysphagia and rash within a week of commencing treatment. He was started onazathioprine at 2mg/kg in December2018. Discussion: The SAE-1 autoantibody targets the auto-antigen SUMO-1 facilitating protein sumoylation. Previous cohort studies have shown skin manifestations and dysphagia as predominant clinical characteristics in SAE-1 dermatomyositis. Our patient had features of interstitial lung disease which has previously been reported as rare in such patients. Our patient also had a normal serial CK and transaminases despite having proximalclinicalweakness and onactivity onradiological modality. Our patient had SAE-1 positive dermatomyositis which has responded quickly to corticosteroids. Azathioprine was chosen ahead of other immunosuppressive therapy after discussion with the dermatology team as cutaneous manifestations were predominant. The patient remains in remissionon azathioprine. Key learning points: SAE-1 dermatomyositis is very steroid responsive and remission can be maintained on azathioprine when there are widespreadcutaneous manifestations, dysphagiaand mild ILD. The case serves as an important reminder that CK levels can be normal in active myositis. A normal CK should not stop further investigations where clinical suspicion forinflammatory myopathyremains high. SAE-1 positive dermatomyositis is a heterogeneous inflammatory myopathy. Our patient had skin manifestations and dysphagia as reported in many previous case reports however they also had features in keeping with organising pneumonia which has been reported as a rarer finding in SAE-1 dermatomyositis. A multi-disciplinary approach to such patients is paramount. This case involved team work between rheumatology, dermatology, respiratory medicine and radiology. Conflicts of interest: The authors have declared no conflicts of interest.
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